Crinetics Pharmaceuticals, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for CRNX, updated each market day.
CRNX AI Sentiment
AI predicts Crinetics Pharmaceuticals, Inc. stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Sector
Exchange
Market Cap
$4,149,472,227
Cap Tier
Employees
594
Headquarters
SAN DIEGO, CA
Listed Since
July 18, 2018
Website
CRNX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CRNX Volatility
Crinetics Pharmaceuticals, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
